Doreen Koenning · Antibody researcher
Doreen Koenning is a postdoctoral researcher and a member of the healthcare R&D trainee program for Merck KGaA, Darmstadt, Germany. She joined the company's Antibody-Drug Conjugates Department in 2017. Her work focuses on the development of novel antibody-based formats with the purpose of exploring novel cancer treatments. Koenning studied biomolecular engineering in Darmstadt and received her PhD in 2017. During that time she focused on protein engineering of shark antibodies, and also gained additional experience in the engineering of alternative scaffold proteins during a research stay at MIT. She is passionate about exploring unexpected solutions to scientific challenges.